Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
CC transcript
Inv. presentation
Quarterly results
Director departure
Emergent BioSolutions Inc. (EBS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/31/2023 8-K Investor presentation
Docs: "Emergent BioSolutions Inc. 2023 Annual Meeting of Stockholders May 25, 2023 Agenda 22023 Virtual Annual Meeting of Stockholders INTRODUCTION 1. Call to"
01/10/2022 8-K Investor presentation
Docs: "Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results",
"Our Path Forward Robert G. Kramer President"
01/11/2021 8-K Quarterly results
01/13/2020 8-K Investor presentation
Docs: "EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2019 FINANCIAL RESULTS AND PROVIDES 2020 FINANCIAL FORECAST",
"Corporate Overview 38th Annual J.P. Morgan Healthcare Conference Robert G. Kramer Sr. President and Chief Executive Officer January 14, 2020"
01/07/2019 8-K Investor presentation
Docs: "EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2018 FINANCIAL RESULTS AND PROVIDES 2019 FINANCIAL",
"Corporate slide deck"
01/08/2018 8-K Investor presentation
Docs: "EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL",
"Corporate slide deck"
01/09/2017 8-K Form 8-K - Current report
01/11/2016 8-K Investor presentation
Docs: "· 2015 Preliminary Estimates: o Total revenues of $520 to $525 million, a 16% increase over 2014 o GAAP net income of $60 to $64 million, a 69% increase over 2014 o Adjusted net income of $73 to $77 million, a 38% increase over 2014 o EBITDA of $130 to $134 million, a 43% increase over 2014 o Year-end cash of approximately $310 million · 2016 Forecast: o Total revenues of $600 to $630 million o GAAP net income of $75 to $85 million o Adjusted net income of $90 to $100 million o EBITDA of $150 to $160 million · 2020 Key Financial and Operational Goals: o Annual revenue of $1B o >10% of revenue from ex-US markets o Net income CAGR of >20% o Six products in clinical or advanced development, with at least three being dual use, prioritizing those with third party funding",
"· 2015 Preliminary Estimates: o Total revenues of $520 to $525 million, a 16% increase over 2014 o GAAP net income of $60 to $64 million, a 69% increase over 2014 o Adjusted net income of $73 to $77 million, a 38% increase over 2014 o EBITDA of $130 to $134 million, a 43% increase over 2014 o Year-end cash of approximately $310 million · 2016 Forecast: o Total revenues of $600 to $630 million o GAAP net income of $75 to $85 million o Adjusted net income of $90 to $100 million o EBITDA of $150 to $160 million · 2020 Key Financial and Operational Goals: o Annual revenue of $1B o >10% of revenue from ex-US markets o Net income CAGR of >20% o Six products in clinical or advanced development, with at least three being dual use, prioritizing those with third party funding",
"Corporate slide deck",
"Corporate slide deck"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy